<DOC>
	<DOCNO>NCT02989857</DOCNO>
	<brief_summary>Study AG120-C-005 Phase 3 , multicenter , randomize , double-blind , placebo-controlled study orally administer AG-120 . Subjects , personnel involve evaluation subject ' response treatment ( e.g. , Investigators , study coordinator , study pharmacist ) , designate Sponsor team member blind study treatment . Subjects require histologically-confirmed diagnosis IDH1 gene-mutated cholangiocarcinoma eligible curative resection , transplantation , ablative therapy prior enrollment.IDH1 mutation test perform participate investigative site . Subjects must progression disease receive least 1 2 prior treatment regimen advance disease ( nonresectable metastatic ) . All subject must receive either gemcitabine 5 fluorouracil ( 5-FU ) base chemotherapy regimen .</brief_summary>
	<brief_title>Study AG-120 Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations ( ClarIDHy )</brief_title>
	<detailed_description />
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<criteria>1 . Be ≥18 year age . 2 . Have histopathological diagnosis ( fresh bank tumor biopsy sample , preferably collect within last 3 year ) nonresectable metastatic cholangiocarcinoma eligible curative resection , transplantation , ablative therapy . 3 . Have document IDH1 genemutated disease ( fresh tumor biopsy recent bank tumor tissue available ) base central laboratory testing ( R132C/L/G/H/S mutation variant test ) . 4 . Have ECOG PS score 0 1 5 . Have expect survival ≥3 month . 6 . Have least one evaluable measurable lesion define RECIST v1.1 . Subjects receive prior local therapy ( include limit embolization , chemoembolization , radiofrequency ablation , radiation therapy ) eligible provide measurable disease fall outside treatment field within field show ≥20 % growth size since posttreatment assessment . 7 . Have document disease progression follow least 1 2 prior systemic regimen advance disease ( nonresectable metastatic ) . Subjects must receive least 1 gemcitabine 5FUcontaining regimen advance cholangiocarcinoma . Subjects received systemic adjuvant chemotherapy permit provide documented disease progression within 6 month complete therapy . Exclusion criterion : 1 . Received prior IDH inhibitor . 2 . Received systemic anticancer therapy investigational agent &lt; 2 week prior Day 1 ( washout prior immune base anticancer therapy 4 week ) . In addition , first dose study treatment occur period ≥5 halflives investigational agent elapse . 3 . Received radiotherapy metastatic site disease &lt; 2 week prior Day 1 . 4 . Underwent hepatic radiation , chemoembolization , radiofrequency ablation &lt; 4 week prior Day 1 . 5 . Have know symptomatic brain metastasis require steroid . Subjects previously diagnose brain metastasis eligible complete treatment recover acute effect radiation therapy surgery prior study entry , discontinue corticosteroid treatment metastasis least 4 week radiographically stable disease least 3 month prior study entry . Note : 10 mg per day prednisone equivalent allow .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>IDH1</keyword>
</DOC>